Since then, researchers began to investigate gut-derived insulin secretagogues; and incretin-based therapies currently have become the preferred first injection therapy for T2DM treatment, due to their strong glycemic control effect and remarkable safety profile [8]. This evidence concerns the gene GCG and type 2 diabetes mellitus.